D. Western Therapeutics Institute Inc
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract su… Read more
D. Western Therapeutics Institute Inc (6DW) - Net Assets
Latest net assets as of June 2025: €884.57 Million EUR
Based on the latest financial reports, D. Western Therapeutics Institute Inc (6DW) has net assets worth €884.57 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.51 Billion) and total liabilities (€628.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €884.57 Million |
| % of Total Assets | 58.45% |
| Annual Growth Rate | -4.15% |
| 5-Year Change | -66.09% |
| 10-Year Change | -65.24% |
| Growth Volatility | 46.87 |
D. Western Therapeutics Institute Inc - Net Assets Trend (2009–2024)
This chart illustrates how D. Western Therapeutics Institute Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for D. Western Therapeutics Institute Inc (2009–2024)
The table below shows the annual net assets of D. Western Therapeutics Institute Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €733.87 Million | -42.66% |
| 2023-12-31 | €1.28 Billion | -31.69% |
| 2022-12-31 | €1.87 Billion | -7.94% |
| 2021-12-31 | €2.04 Billion | -5.95% |
| 2020-12-31 | €2.16 Billion | +53.68% |
| 2019-12-31 | €1.41 Billion | +8.31% |
| 2018-12-31 | €1.30 Billion | -37.97% |
| 2017-12-31 | €2.10 Billion | -27.16% |
| 2016-12-31 | €2.88 Billion | +36.30% |
| 2015-12-31 | €2.11 Billion | +118.26% |
| 2010-12-31 | €967.18 Million | -30.19% |
| 2009-12-31 | €1.39 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to D. Western Therapeutics Institute Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 256954600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €4.47 Billion | 608.63% |
| Total Equity | €733.87 Million | 100.00% |
D. Western Therapeutics Institute Inc Competitors by Market Cap
The table below lists competitors of D. Western Therapeutics Institute Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cloud Technologies S.A
WAR:CLD
|
$22.76 Million |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
$22.77 Million |
|
Nam Kwang Cons
KO:001260
|
$22.77 Million |
|
Tribhovandas Bhimji Zaveri Limited
NSE:TBZ
|
$22.78 Million |
|
ClearVue Technologies Limited
OTCQX:CVUEF
|
$22.76 Million |
|
KEYEAST.Co.Ltd
KQ:054780
|
$22.75 Million |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
$22.75 Million |
|
Miwon Holdings Co. Ltd
KO:107590
|
$22.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in D. Western Therapeutics Institute Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,279,765,000 to 733,869,000, a change of -545,896,000 (-42.7%).
- Net loss of 1,290,305,000 reduced equity.
- Share repurchases of 699,000 reduced equity.
- New share issuances of 710,030,000 increased equity.
- Other factors increased equity by 35,078,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.29 Billion | -175.82% |
| Share Repurchases | €699.00K | -0.1% |
| Share Issuances | €710.03 Million | +96.75% |
| Other Changes | €35.08 Million | +4.78% |
| Total Change | €- | -42.66% |
Book Value vs Market Value Analysis
This analysis compares D. Western Therapeutics Institute Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €76.20 | €0.50 | x |
| 2018-12-31 | €47.95 | €0.50 | x |
| 2019-12-31 | €53.02 | €0.50 | x |
| 2020-12-31 | €73.98 | €0.50 | x |
| 2021-12-31 | €68.36 | €0.50 | x |
| 2022-12-31 | €60.17 | €0.50 | x |
| 2023-12-31 | €39.83 | €0.50 | x |
| 2024-12-31 | €17.63 | €0.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently D. Western Therapeutics Institute Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -175.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -273.61%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 2.27x
- Recent ROE (-175.82%) is below the historical average (-42.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -28.36% | 0.00% | 0.00x | 1.02x | €-531.43 Million |
| 2010 | -43.26% | 0.00% | 0.00x | 1.02x | €-515.11 Million |
| 2015 | -15.45% | -485.25% | 0.03x | 1.12x | €-487.60 Million |
| 2016 | -9.26% | -150.90% | 0.06x | 1.06x | €-527.33 Million |
| 2017 | -78.14% | -615.48% | 0.09x | 1.44x | €-1.76 Billion |
| 2018 | -59.45% | -255.69% | 0.14x | 1.65x | €-874.95 Million |
| 2019 | 9.56% | 22.95% | 0.29x | 1.42x | €-6.10 Million |
| 2020 | -12.76% | -77.65% | 0.13x | 1.27x | €-492.49 Million |
| 2021 | -7.42% | -35.95% | 0.17x | 1.23x | €-349.69 Million |
| 2022 | -23.13% | -95.89% | 0.15x | 1.59x | €-615.43 Million |
| 2023 | -63.48% | -189.65% | 0.18x | 1.85x | €-940.39 Million |
| 2024 | -175.82% | -273.61% | 0.28x | 2.27x | €-1.36 Billion |
Industry Comparison
This section compares D. Western Therapeutics Institute Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| D. Western Therapeutics Institute Inc (6DW) | €884.57 Million | -28.36% | 0.71x | $22.76 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |